CVSI on OTC
CV Sciences, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Pyxis Oncology, Inc., Arbutus Biopharma or Opus Genetics, Inc., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
49.0%Gross margin3
-3.4%Operating margin3
-6.9%Net margin3
-12.2%Revenue growth, 20253
-65.3%Return on equity3
0.26×Debt to equity3
-$516.0KFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue48¢$7.0M
- Research and development1¢$122.0K
- Selling, general and admin52¢$7.6M
- Income tax0¢$9.0K
Out of $13.8M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Product sales, net | $13.8M | $15.7M |
| Cost of goods sold | $7.0M | $8.5M |
| Gross profit | $6.8M | $7.2M |
| Research and development | $122.0K | $118.0K |
| Selling, general and administrative | $7.6M | $9.2M |
| Benefit from reversal of accrued payroll taxes (Note 12) | -$522.0K | $0 |
| Total operating expenses | $7.2M | $9.4M |
| Operating loss | -$470.0K | -$2.2M |
| Gain on extinguishment of debt | -$38.0K | $0 |
| Interest expense, net | $517.0K | $212.0K |
| Loss before income taxes | -$949.0K | -$2.4M |
| Income tax expense (benefit) | $9.0K | -$8.0K |
| Net loss | -$958.0K | -$2.4M |
| Weighted average common shares outstanding, basic (in shares) | 184.3M shares | 175.6M shares |
| Weighted average common shares outstanding, diluted (in shares) | 184.3M shares | 175.6M shares |
| Net loss per common share, basic (in USD per share) | -$0.01 | -$0.01 |
| Net loss per common share, basic diluted (in USD per share) | -$0.01 | -$0.01 |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash | $278.0K | $454.0K | |
| Accounts receivable, net | $402.0K | $522.0K | |
| Inventory | $4.1M | $4.9M | |
| Prepaid expenses and other | $366.0K | $370.0K | |
| Total current assets | $5.1M | $6.2M | |
| Property and equipment, net | $344.0K | $399.0K | |
| Right of use assets | $347.0K | $94.0K | |
| Intangibles, net | $76.0K | $93.0K | |
| Goodwill | $1.0M | $971.0K | $342.0K |
| Other assets | $47.0K | $127.0K | |
| Total assets | $7.0M | $7.9M | |
| Accounts payable | $1.0M | $1.9M | |
| Accrued expenses | $2.4M | $3.4M | |
| Crrent portion of operating lease liability | $247.0K | $83.0K | |
| Current portion of long-term debt, net of discounts and issuance costs | $1.3M | $677.0K | |
| Total current liabilities | $5.0M | $6.1M | |
| Operating lease liability | $100.0K | $19.0K | |
| Debt, net of discounts and issuance costs | $387.0K | $0 | |
| Deferred tax liability | $7.0K | $4.0K | |
| Total liabilities | $5.5M | $6.1M | |
| Common stock, par value $0.0001; 790,000 shares authorized; 184,264 shares issued and outstanding as of December 31, 2025 and 2024 | $18.0K | $18.0K | |
| Additional paid-in capital | $89.3M | $88.8M | |
| Accumulated deficit | -$87.9M | -$87.0M | |
| Accumulated other comprehensive income (loss) | $59.0K | -$15.0K | |
| Total stockholders' equity | $1.5M | $1.8M | $2.9M |
| Total liabilities and stockholders' equity | $7.0M | $7.9M | |
| Preferred stock par value (in USD per share) | $0.00 | $0.00 | |
| Preferred stock authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock issued (in shares) | 1.0K shares | 1.0K shares | |
| Preferred stock outstanding (in shares) | 0 shares | 0 shares | |
| Common stock par value (in USD per share) | $0.00 | $0.00 | |
| Common stock authorized (in shares) | 790.0M shares | 790.0M shares | |
| Common stock issued (in shares) | 184.3M shares | 184.3M shares | |
| Common stock outstanding (in shares) | 184.3M shares | 184.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$958.0K | -$2.4M |
| Depreciation and amortization | $192.0K | $334.0K |
| Stock-based compensation | $497.0K | $258.0K |
| Amortization of debt discount | $513.0K | $209.0K |
| Amortization of right of use assets | $238.0K | $122.0K |
| Gain in fair value of contingent consideration liabilities | $0 | -$188.0K |
| Gain on debt extinguishment | -$38.0K | $0 |
| Benefit from reversal of accrued payroll tax (Note 12) | -$522.0K | $0 |
| Deferred taxes | $3.0K | -$15.0K |
| Other | $138.0K | $355.0K |
| Accounts receivable, net | $124.0K | -$84.0K |
| Inventory | $827.0K | $803.0K |
| Prepaid expenses and other | $166.0K | $342.0K |
| Accounts payable and accrued expenses | -$1.3M | -$467.0K |
| Operating lease liability | -$245.0K | -$136.0K |
| Net cash flows used in operating activities | -$407.0K | -$861.0K |
| Purchases of property and equipment | -$109.0K | -$18.0K |
| Acquisition of business, net of cash acquired | $0 | -$10.0K |
| Net cash flows used in investing activities | -$109.0K | -$28.0K |
| Proceeds from note payable | $1.6M | $900.0K |
| Debt issuance costs related to note payable | -$90.0K | -$5.0K |
| Repayment of note payable | -$1.1M | -$622.0K |
| Repayment of unsecured debt | -$173.0K | -$241.0K |
| Net cash flows provided by financing activities | $337.0K | $32.0K |
| Effect of exchange rate changes on cash | $3.0K | -$6.0K |
| Net decrease in cash | -$176.0K | -$863.0K |
| Interest paid | $6.0K | $8.0K |
| Purchase of insurance through issuance of note payable (Note 8) | $160.0K | $177.0K |
| Right of use asset financed by lease liabilities | $486.0K | $49.0K |
| Debt issuance cost for note payable | -$550.0K | -$284.0K |
| Services paid with common stock | $60.0K | $182.0K |
| Fair value of assets acquired, excluding cash | $0 | $414.0K |
| Liabilities assumed | $0 | -$73.0K |
| Goodwill on acquisition | $0 | $640.0K |
| Common stock consideration | $0 | -$871.0K |
| Contingent consideration | $0 | -$100.0K |
| Cash paid for acquisition | $0 | $10.0K |
Former names
Recent filings
- Sep 9, 2026SCHEDULE 13G
- Sep 9, 20263 PRIMARY DOCUMENT
- Sep 9, 20264 PRIMARY DOCUMENT
- Aug 13, 20268-K
- Aug 13, 202610-Q
- Jun 4, 20268-K
- May 15, 202610-Q
- May 14, 20268-K
- Apr 15, 2026DEF 14A
- Apr 10, 20268-K
- Mar 26, 20268-K
- Mar 26, 202610-K
- Mar 10, 20268-K
- Nov 13, 20258-K
- Nov 13, 202510-Q
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10